publication date: Oct. 30, 2015

Lilly’s PACE Continuous Innovation Indicators Visualize Progress and Value in Research

 

Lilly Oncology has launched a novel value assessment tool that aggregates 40 years of oncology data to measure progress and identify unmet needs in cancer treatments.

The tool, called PACE Continuous Innovation Indicators, or PACE CII, is an effort to visualize progress in cancer treatments with the flexibility to accommodate different cancer subtypes.

PACE CII, launched earlier this year, contains data on 12 solid tumors: namely cancers of the breast, colon, rectum, liver, pancreas, and prostate, as well as melanoma, non-small cell lung cancer, gastric cancer, renal cancer, testicular cancer and endometrial cancer.

Users can make comparisons across tumor types, disease stages and treatments to identify where unmet needs still exist.

“The actual goal of this tool is to foster this better understanding of innovation and progress for the entire cancer community,” said Jax Ferguson, senior director of global oncology corporate affairs at Lilly Oncology. “What we’re really hoping for is that folks who use it—these diverse stakeholders—are going to use the tool to make their own conclusion about value and progress.”

PACE CII does not include any economic inputs in the database, said Ferguson, who runs the PACE (Patient Access to Cancer care Excellence) organization.

“It is purely a scientific assessment of value, which we believe is important,” Ferguson said to The Cancer Letter. “What we want to do is help people understand the scientific value of these treatments, and very importantly, want to make sure that this becomes … Continue reading 41-40 Lilly’s PACE Continuous Innovation Indicators Visualize Progress and Value in Research

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.